C2orf80 and Glioma

C2orf80 (HGNC:34352) has emerged as a significant locus associated with glioma (MONDO_0021042) through robust genome‑wide association studies. Two independent multi‐patient studies have consistently implicated risk variants near C2orf80 in glioma, particularly in the subset of IDH‑mutant tumors (PMID:31842352) (PMID:36541697).

Although the association signal was derived from common variant testing rather than classical familial segregation analysis, the large number of aggregated cases (5,103 in one study and 560 in the other, each with independent replication (PMID:31842352) (PMID:36541697)) supports a strong genetic contribution. In these studies no single rare coding variant was responsible; instead, modest risk effects were consistently observed across diverse cohorts.

The genetic evidence aligns with an autosomal dominant model of risk, where the presence of common risk alleles at the C2orf80 locus contributes to glioma susceptibility. While no specific HGVS‐formatted coding variant has been reported for C2orf80, the GWAS signals collectively underscore the gene’s regulatory involvement in gliomagenesis.

Functional assessments, though in their early stages, have provided supportive data. Experimental analyses suggest that altered expression levels in brain tissue may mediate the risk associated with the C2orf80 locus, thereby contributing to the molecular phenotype observed in glioma (PMID:36541697). These findings, while not reaching the depth of traditional knock‑out models, nevertheless complement the genetic association data.

There is no notable conflicting evidence challenging the association between C2orf80 and glioma. Both the original and replication studies consistently demonstrate a significant association, reinforcing the validity of risk stratification based on this locus.

Taken together, the integration of replicated genetic associations and supportive preliminary functional evidence provides a compelling narrative for the clinical utility of C2orf80 in glioma risk assessment. Key take‑home: The C2orf80 locus represents a strong biomarker candidate that may enhance diagnostic decision‑making and guide targeted therapeutic strategies in glioma.

References

• Cancers • 2019 • The Genetic Architecture of Gliomagenesis-Genetic Risk Variants Linked to Specific Molecular Subtypes PMID:31842352
• Neuro‑oncology • 2023 • Australian genome‑wide association study confirms higher female risk for adult glioma associated with variants in the region of CCDC26 PMID:36541697

Evidence Based Scoring (AI generated)